PhaseBio Pharmaceuticals Inc
NASDAQ:PHAS
Intrinsic Value
PhaseBio Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of novel therapies for cardiopulmonary diseases. [ Read More ]
There is not enough data to reliably calculate the intrinsic value of PHAS.
PhaseBio Pharmaceuticals Inc's market capitalization is 2m USD.
PHAS stock price is 0.04 USD.
PHAS.
PHAS. Open DCF Valuation
PHAS. Open Relative Valuation
PHAS.
PHAS's Revenue has dropped by 92% over the past 12 months.
PHAS's ROE (Return on Equity) has significantly increased in the last 3 years from -359% to 151%.
PHAS's ROIC (Return on Invested Capital) has significantly increased in the last 3 years from -574% to -505%, and is approaching profitability.
PHAS has negative Operating Income for the last twelve months.
PHAS has negative Net Income for the last twelve months.
PHAS's ROE (Return on Equity) for the past 12 months is very high and is equal to 151%.
PHAS's ROIC (Return on Invested Capital) for the past 12 months is negative and is equal to -505%.
PHAS's short-term liabilties (25m USD) exceed its short-term assets (12m USD).
PHAS has negative Free Cash Flow for the last twelve months.
PHAS's long-term liabilties (140m USD) exceed its long-term assets (22m USD).
PHAS has negative three-year average ROE (Return on Equity): -162%. The company is not efficient at transforming stockholders' equity into net income.
PHAS has negative three-year average ROIC (Return on Invested Capital): -2 189%. The company is not efficient at using invested capital to generate operating income.
PHAS's D/E (Debt to Equity) is very low and is equal to 0.
PHAS's Altman Z-Score is very low and is equal to -42.98.
PHAS doesn't generate enough operating income (-104m USD) to safely cover interest payments on its debt (338k USD).
Fundamental Analysis
PhaseBio Pharmaceuticals Inc
Balance Sheet Decomposition
PhaseBio Pharmaceuticals Inc
| Current Assets | 11.6m |
| Cash & Short-Term Investments | 7.8m |
| Other Current Assets | 3.8m |
| Non-Current Assets | 10.6m |
| PP&E | 10.5m |
| Other Non-Current Assets | 58k |
| Current Liabilities | 24.7m |
| Accounts Payable | 6.3m |
| Accrued Liabilities | 12.9m |
| Other Current Liabilities | 5.5m |
| Non-Current Liabilities | 114.9m |
| Other Non-Current Liabilities | 114.9m |
Earnings Waterfall
PhaseBio Pharmaceuticals Inc
|
Revenue
|
818k
USD
|
|
Operating Expenses
|
-105m
USD
|
|
Operating Income
|
-104.2m
USD
|
|
Other Expenses
|
1.4m
USD
|
|
Net Income
|
-102.8m
USD
|
Free Cash Flow Analysis
PhaseBio Pharmaceuticals Inc
PHAS Profitability Score
Profitability Due Diligence
PhaseBio Pharmaceuticals Inc's profitability score is 27/100. The higher the profitability score, the more profitable the company is.
Score
PhaseBio Pharmaceuticals Inc's profitability score is 27/100. The higher the profitability score, the more profitable the company is.
PHAS Solvency Score
Solvency Due Diligence
PhaseBio Pharmaceuticals Inc's solvency score is 25/100. The higher the solvency score, the more solvent the company is.
Score
PhaseBio Pharmaceuticals Inc's solvency score is 25/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
PHAS Price Targets Summary
PhaseBio Pharmaceuticals Inc
Ownership
PHAS Insider Trading
Buy and sell transactions by insiders
| Period | Sold | Bought | Net |
|---|---|---|---|
| 3 Months |
|
|
|
| 6 Months |
|
|
|
| 9 Months |
|
|
|
| 12 Months |
|
|
|
Shareholder Return
PHAS Price
PhaseBio Pharmaceuticals Inc
| Average Annual Return | -40.55% |
| Standard Deviation of Annual Returns | 15.65% |
| Max Drawdown | -100% |
| Market Capitalization | 2m USD |
| Shares Outstanding | 49 182 800 |
| Percentage of Shares Shorted | 5.11% |
Company Profile
PhaseBio Pharmaceuticals Inc
Country
Industry
Market Cap
Dividend Yield
Description
PhaseBio Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of novel therapies for cardiopulmonary diseases. The company is headquartered in Malvern, Pennsylvania and currently employs 60 full-time employees. The company went IPO on 2018-10-18. The Company’s product pipeline includes Bentracimab (PB2452), PB6440 (for treatment-resistant Hypertension), pemziviptadil (PB1046), GLP2-ELP and CNP-ELP. The firm conducting REVERSE-IT, its pivotal Phase III clinical trial of bentracimab. PB2452 is a novel recombinant human monoclonal antibody antigen-binding fragment, designed to reverse the antiplatelet activity of ticagrelor in the event of major bleeding. PB6440 is an oral selective aldosterone synthase inhibitor for treatment of resistant hypertension. Pemziviptadil (PB1046), is a novel, subcutaneously-injected VIP analogue, which is a recombinant fusion protein composed of VIP and its proprietary ELP technology. ELP technology platform is a growth engine for additional medicines for cardiovascular diseases.
You don't have any saved screeners yet
